Literature DB >> 31396327

Expression and clinical significance of KLK5-8 in endometrial cancer.

Shu Lei1,2, Qi Zhang1, Fufen Yin2, Xiangjun He1, Jianliu Wang2.   

Abstract

Kallikrein-related peptidase (KLK) family is one of the major serine proteases in tumor microenvironment, which plays a crucial role in cancer invasion and metastasis. A number of KLK family members have been found to be upregulated or downregulated in some cancers, and some KLKs may be potential biomarkers for cancers. However, little is known about the role of KLKs in endometrial carcinoma (EC). In this study, we analyzed the mRNA sequencing data of EC from The Cancer Genome Atlas (TCGA) public database and found that the higher expression of KLK family members 5-8 (KLK5-8) was associated with an aggressive clinicopathologic phenotype and worse prognosis in EC patients. High expression of KLK5-8 was also confirmed in our patients with advanced stage and high-grade EC, as well as in a highly invasive cell line. Our study also demonstrated the differences between the subcellular localization of KLK5-8 and the co-expression of different splicing variants of KLK5-8 in EC cells, suggesting that various isoforms of KLK5-8 may work synergistically to regulate invasion and migration. We found that the elevation of more KLKs in a patient's sample indicated a higher risk of worse survival. Combination of KLK5-8 was shown to be an independent prognostic factor for overall survival by multivariate Cox regression (hazard ratio: 2.215, 95% confidence interval: 1.045-4.694, P=0.038), and may be a promising biomarker.

Entities:  

Keywords:  Kallikrein-related peptidases; TCGA database; endometrial carcinoma; prognosis; splicing variant

Year:  2019        PMID: 31396327      PMCID: PMC6684924     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  23 in total

Review 1.  The human kallikrein gene family: new biomarkers for ovarian cancer.

Authors:  George M Yousef; Eleftherios P Diamandis
Journal:  Cancer Treat Res       Date:  2009

2.  Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer.

Authors:  Chris Planque; Yun-Hee Choi; Serge Guyetant; Nathalie Heuzé-Vourc'h; Laurent Briollais; Yves Courty
Journal:  Clin Chem       Date:  2010-04-01       Impact factor: 8.327

3.  Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer.

Authors:  Jong-Tae Kim; Eun Young Song; Kyung-Sook Chung; Min Ah Kang; Jae Wha Kim; Sang Jick Kim; Young Il Yeom; Joo Heon Kim; Kyo Hyun Kim; Hee Gu Lee
Journal:  Cancer       Date:  2010-12-23       Impact factor: 6.860

4.  Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.

Authors:  Alessandro D Santin; Eleftherios P Diamandis; Stefania Bellone; Antoninus Soosaipillai; Stefania Cane; Michela Palmieri; Alexander Burnett; Juan J Roman; Sergio Pecorelli
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

Review 5.  The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions.

Authors:  J Clements; J Hooper; Y Dong; T Harvey
Journal:  Biol Chem       Date:  2001-01       Impact factor: 3.915

6.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

7.  Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications.

Authors:  Manal Gabril; Nicole M White; Madeleine Moussa; Tsz-fung F Chow; Shereen M Metias; Eman Fatoohi; George M Yousef
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

8.  Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.

Authors:  Ying Dong; Aneel Kaushal; Maria Brattsand; Jim Nicklin; Judith A Clements
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

Review 9.  An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers.

Authors:  George M Yousef; Eleftherios P Diamandis
Journal:  Clin Biochem       Date:  2003-09       Impact factor: 3.281

10.  Kallikrein gene downregulation in breast cancer.

Authors:  G M Yousef; G M Yacoub; M-E Polymeris; C Popalis; A Soosaipillai; E P Diamandis
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  7 in total

1.  Low expression of developing brain homeobox 2 (Dbx2) may serve as a biomarker to predict poor prognosis in endometrial cancer.

Authors:  Xinlu Zhang; Yaping Wang; Shujun Zhao; Qiaohong Qin; Min Zhang; Yi Jiang; Hai Zhu; Hongyu Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 2.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

3.  Clinical significance of kallikrein 5 as a novel prognostic biomarker in gastric adenocarcinoma.

Authors:  Xiaokaiti Abuduhadeer; Xincai Xu; Kamali Aihesan; Maimaiti Yilihamu; Yanjun Zhao; Wenbin Zhang
Journal:  J Clin Lab Anal       Date:  2021-09-12       Impact factor: 2.352

4.  KLK8 promotes the proliferation and metastasis of colorectal cancer via the activation of EMT associated with PAR1.

Authors:  Qing Hua; Zhirong Sun; Yi Liu; Xuefang Shen; Weiwei Zhao; Xiaoyan Zhu; Pingbo Xu
Journal:  Cell Death Dis       Date:  2021-09-22       Impact factor: 8.469

Review 5.  SPINKs in Tumors: Potential Therapeutic Targets.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Minglin Zhang; Jie Chen; Xiaolan Li; Linlin Xiao; Jiajia Wang; Qian Long; Jianguo Liu; Xiaoyan Guan
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

6.  CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer.

Authors:  Yaping Wang; Shujun Zhao; Qiaohong Qin; Xiang Gao; Xinlu Zhang; Min Zhang; Yi Jiang; Xiaorong Ji; Hai Zhu; Xin Zhao; Hongyu Li
Journal:  PLoS One       Date:  2022-01-25       Impact factor: 3.240

Review 7.  Endometrial cancer-is our knowledge changing?

Authors:  Milena Králíčková; Vaclav Vetvicka; Antonio Simone Laganà
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.